Severe acute respiratory syndrome coronavirus-2: An era of struggle and discovery leading to the emergency use authorization of treatment and prevention measures based on computational analysis

Severe acute respiratory syndrome-Coronavirus-2 (SARS-CoV-2), a novel betacoronavirus, has surprised the world with its disease spread and mortality rate. SARS-CoV-2 is a positive-sense, enveloped RNA virus that can infect various organs of the body, potentially leading to multiple organ dysfunction and eventual death. While various medications have received emergency use authorizations (EUAs) for the treatment of Coronavirus disease-2019 (COVID-19), as of April 30, 2021, only one drug has been Food and Drug Administration (FDA)-approved: remdesivir. Currently, three vaccines have received EUAs in the United States, but none are FDA-approved. This shortage of treatments and prevention measures is extremely problematic. Thus computational approaches would provide important data about drug resistance and variants. Such data will be useful for the development of drugs and vaccines. This chapter is a synopsis of SARS-CoV-2 clinical presentation, COVID-19 symptomology, treatment, prevention mechanisms, and SARS-CoV-2 variants using computational analysis.